AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Karyopharm Therapeutics I... (KPTI)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.67

-0.03 (-4.05%)

At close: Jan 17, 2025, 3:59 PM

0.66

-0.74%

After-hours Jan 17, 2025, 04:00 PM EST

Karyopharm Therapeutics Inc. Revenue Breakdown

Quarter	Sep 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022
License and Service Revenue	8.75M	6.41M	4.45M	5.56M	5.61M	8.74M	437.00K	1.62M	6.53M
License and Service Revenue Growth	+36.64%	+44.02%	-20.06%	-0.84%	-35.78%	+1899.31%	-72.99%	-75.23%	n/a
Health Care, Other Revenue	241.00K	203.00K	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Health Care, Other Revenue Growth	+18.72%	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a

Revenue by Geography

Quarter	Dec 31, 2020
Canada Revenue	5.00M
Canada Revenue Growth	n/a

Operating Expense Breakdown

Quarter	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016	Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
Selling, General, and Administrative Revenue	27.63M	31.07M	29.55M	30.69M	30.80M	34.48M	35.91M	34.65M	34.65M	37.34M	38.77M	34.56M	35.10M	36.53M	37.65M	33.93M	30.97M	30.84M	30.68M	28.39M	25.27M	24.66M	27.10M	18.77M	12.97M	9.49M	7.62M	6.15M	5.82M	6.63M	6.26M	6.54M	5.90M	5.96M	5.55M	5.26M	4.76M	6.16M	5.40M
Selling, General, and Administrative Revenue Growth	-11.07%	+5.15%	-3.71%	-0.38%	-10.66%	-3.97%	+3.63%	+0.01%	-7.21%	-3.69%	+12.17%	-1.54%	-3.90%	-2.97%	+10.97%	+9.57%	+0.40%	+0.54%	+8.06%	+12.36%	+2.45%	-9.01%	+44.39%	+44.77%	+36.64%	+24.51%	+23.86%	+5.76%	-12.31%	+5.92%	-4.23%	+10.92%	-0.99%	+7.24%	+5.51%	+10.54%	-22.66%	+14.04%	n/a
Research and Development Revenue	36.13M	38.28M	35.34M	39.30M	35.55M	31.48M	32.34M	30.93M	31.36M	44.31M	42.06M	44.00M	45.81M	33.98M	37.05M	37.19M	37.04M	42.59M	34.00M	31.58M	26.27M	26.52M	37.97M	38.89M	36.43M	44.73M	41.32M	34.83M	25.24M	23.12M	24.08M	20.67M	19.89M	24.58M	21.80M	24.06M	25.92M	27.01M	20.75M
Research and Development Revenue Growth	-5.61%	+8.32%	-10.09%	+10.55%	+12.95%	-2.67%	+4.55%	-1.36%	-29.23%	+5.34%	-4.41%	-3.94%	+34.80%	-8.28%	-0.36%	+0.40%	-13.05%	+25.29%	+7.66%	+20.21%	-0.93%	-30.17%	-2.36%	+6.76%	-18.57%	+8.26%	+18.63%	+38.02%	+9.16%	-4.00%	+16.51%	+3.91%	-19.07%	+12.77%	-9.43%	-7.17%	-4.01%	+30.14%	n/a